Apex BiotechnologyTPE:1733 -0.17%81 Net Margin % is 11.41% as of Dec. 2025, which is 89% above its 10-year median of 6.05. GuruFocus rates TPE:1733 with a GF Score™ of 81/100 and a GF Value™ of NT$30.08 (Fairly Valued). The stock has 2 warning signs investors should review. Among 937 Biotechnology companies, Apex Biotechnology ranks better than 79.83% on this metric.
The historical rank and industry rank for Apex Biotechnology's Net Margin % or its related term are showing as below:
TPE:1733'
s Net Margin % Range Over the Past 10 Years
Min: 0.18 Med: 6.05 Max: 9.49
Current: 8.38
TPE:1733's Net Margin % is ranked better than 79.83% of 937
companies
in the Biotechnology industry
Industry Median: -88.29
vs TPE:1733: 8.38
Apex Biotechnology (TPE:1733) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Apex Biotechnology Net Margin % Related Terms
Apex Biotechnology Net Margin % Historical Data
* Premium members only.
The historical data trend for Apex Biotechnology's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:1733 vs VRTX, REGN, ALNY: Net Margin % Comparison
For the Biotechnology subindustry, Apex Biotechnology's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Apex Biotechnology Net Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Apex Biotechnology's Net Margin % distribution charts can be found below:
* The bar in red indicates where Apex Biotechnology's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Apex Biotechnology (TPE:1733) has a Net Margin % of 11.41% as of Dec. 2025. Net margin is the ratio of total net income to net sales. View historical data on Apex Biotechnology and its competitors. This is 89% above median its historical median of 6.05. Over the past decade, Apex Biotechnology's Net Margin % has ranged from 0.18 to 9.49. According to the industry distribution chart, Apex Biotechnology ranks #189 out of 937 companies in the Biotechnology industry, placing it in the top 20.2%.
Is Apex Biotechnology's Net Margin % too high?
Apex Biotechnology's current Net Margin % of 11.41% is 89% above median its 10-year median of 6.05. Over the past 10 years, this metric has ranged from a low of 0.18 to a high of 9.49. Based on the distribution chart, Apex Biotechnology ranks #189 out of 937 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Apex Biotechnology has a GF Score™ of 81/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Apex Biotechnology's Net Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Apex Biotechnology ranks #189 out of 937 companies for Net Margin %. This places Apex Biotechnology in the top 20% of its industry — outperforming the majority of peers. Historically, Apex Biotechnology's own Net Margin % has ranged from 0.18 to 9.49 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Apex Biotechnology and its competitors. Apex Biotechnology's current Net Margin % is 11.41%, which is 89% above median its own 10-year median of 6.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Apex Biotechnology stock overvalued right now?
Based on GuruFocus' analysis, Apex Biotechnology (TPE:1733) is currently considered Fairly Valued. The stock's GF Value™ is NT$30.08, compared to a current price of NT$29.90 — trading 0.6% below its estimated fair value. The current Net Margin % is 11.41%, which is 89% above median its 10-year median of 6.05. Apex Biotechnology's overall GF Score™ is 81/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Apex Biotechnology (TPE:1733), the current Net Margin % is 11.41% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Apex Biotechnology (TPE:1733) Overvalued in 2026?
Based on GuruFocus' analysis, Apex Biotechnology stock appears to be undervalued.
The current stock price of NT$29.90 is trading 0.6% below its estimated GF Value™ of NT$30.08.
GuruFocus considers Apex Biotechnology to be Fairly Valued.
Key valuation signals for TPE:1733:
Net Margin %: 11.41% (89% above median its 10-year median of 6.05)
GF Value™: NT$30.08 vs. price of NT$29.90 (0.6% below fair value)
No single metric tells the full story. See the TPE:1733 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Apex Biotechnology Corp is engaged in the research, development, production, manufacturing, and sale of biochemical testing instruments and proprietary test strips, as well as the import and export of products and components related to its core business. Its product offerings include diabetes testing kits, blood uric acid monitoring systems, blood lactate monitoring systems, blood haemoglobin monitoring systems, etc. The company generates maximum revenue from the sale of test strips, and the rest from testing meters, electrodes, and other products. Geographically, it derives maximum revenue from the USA, and the rest from Italy, Austria, Taiwan, China, and other markets.
81GF Score
Get the complete analysis for TPE:1733
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:1733 has been successfully added to your 
